APO Research
Talk to an analyst

APO RESEARCH · REPORT

T Cell Specific Surface Glycoprotein CD28

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global T Cell Specific Surface Glycoprotein CD28 Market Outlook and Growth Opportunities 2026

19 December 2025192 pages

Choose your research edition.

Industry ResearchT Cell Specific Surface Glycoprotein CD28 Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal T Cell Specific Surface Glycoprotein CD28 Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal T Cell Specific Surface Glycoprotein CD28 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T Cell Specific Surface Glycoprotein CD28 Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal T Cell Specific Surface Glycoprotein CD28 Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global T Cell Specific Surface Glycoprotein CD28 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for T Cell Specific Surface Glycoprotein CD28 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for T Cell Specific Surface Glycoprotein CD28 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for T Cell Specific Surface Glycoprotein CD28 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the T Cell Specific Surface Glycoprotein CD28 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the T Cell Specific Surface Glycoprotein CD28 market include Johnson & Johnson, TheraMAB LLC, Five Prime Therapeutics Inc, Bristol-Myers Squibb Co and Atox Bio Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global T Cell Specific Surface Glycoprotein CD28 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of T Cell Specific Surface Glycoprotein CD28 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents T Cell Specific Surface Glycoprotein CD28 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the T Cell Specific Surface Glycoprotein CD28 market size, projected growth trends, production technologies, key applications, and end-use industries.

T Cell Specific Surface Glycoprotein CD28 Segment by Company

Johnson & Johnson

TheraMAB LLC

Five Prime Therapeutics Inc

Bristol-Myers Squibb Co

Atox Bio Ltd

T Cell Specific Surface Glycoprotein CD28 Segment by Type

Lulizumab Pegol

FR-104

FPT-155

Others

T Cell Specific Surface Glycoprotein CD28 Segment by Application

Plaque Psoriasis

Acute Renal Failure(ARF)

Solid Tumor

Others

T Cell Specific Surface Glycoprotein CD28 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global T Cell Specific Surface Glycoprotein CD28 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions T Cell Specific Surface Glycoprotein CD28 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify T Cell Specific Surface Glycoprotein CD28 significant trends, drivers, influence factors in global and regions.

6. To analyze T Cell Specific Surface Glycoprotein CD28 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Specific Surface Glycoprotein CD28 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T Cell Specific Surface Glycoprotein CD28 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Specific Surface Glycoprotein CD28.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the T Cell Specific Surface Glycoprotein CD28 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global T Cell Specific Surface Glycoprotein CD28 industry.

Chapter 3: Detailed analysis of T Cell Specific Surface Glycoprotein CD28 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of T Cell Specific Surface Glycoprotein CD28 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of T Cell Specific Surface Glycoprotein CD28 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. T Cell Specific Surface Glycoprotein CD28 Industry Trends Table 2. T Cell Specific Surface Glycoprotein CD28 Industry Drivers Table 3. T Cell Specific Surface Glycoprotein CD28 Industry Opportunities and Challenges Table 4. T Cell Specific Surface Glycoprotein CD28 Industry Restraints Table 5. Global T Cell Specific Surface Glycoprotein CD28 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global T Cell Specific Surface Glycoprotein CD28 Revenue Share by Company (2021-2026) Table 7. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Company (K Units) & (2021-2026) Table 8. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share by Company (2021-2026) Table 9. Global T Cell Specific Surface Glycoprotein CD28 Average Price (US$/Unit) of Company (2021-2026) Table 10. Global T Cell Specific Surface Glycoprotein CD28 Company Ranking, (2024-2026) & (USD Million) Table 11. Global T Cell Specific Surface Glycoprotein CD28 Key Company Manufacturing Base & Headquarters Table 12. Global T Cell Specific Surface Glycoprotein CD28 Company, Product Type & Application Table 13. Global T Cell Specific Surface Glycoprotein CD28 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global T Cell Specific Surface Glycoprotein CD28 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Lulizumab Pegol Table 18. Significant Companies of FR-104 Table 19. Significant Companies of FPT-155 Table 20. Significant Companies of Others Table 21. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Type (2021-2026) & (K Units) Table 23. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Type (2027-2032) & (K Units) Table 24. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share by Type (2021-2026) Table 25. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share by Type (2027-2032) Table 26. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type (2021-2026) Table 30. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Plaque Psoriasis Table 32. Significant Companies of Acute Renal Failure(ARF) Table 33. Significant Companies of Solid Tumor Table 34. Significant Companies of Others Table 35. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Application (2021-2026) & (K Units) Table 37. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Application (2027-2032) & (K Units) Table 38. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share by Application (2021-2026) Table 39. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share by Application (2027-2032) Table 40. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application (2021-2026) Table 44. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application (2027-2032) Table 45. Global T Cell Specific Surface Glycoprotein CD28 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global T Cell Specific Surface Glycoprotein CD28 Sales by Region (2021-2026) & (K Units) Table 47. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Region (2021-2026) Table 48. Global T Cell Specific Surface Glycoprotein CD28 Sales by Region (2027-2032) & (K Units) Table 49. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Region (2027-2032) Table 50. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Region (2021-2026) Table 53. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Region (2027-2032) Table 55. Global T Cell Specific Surface Glycoprotein CD28 Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global T Cell Specific Surface Glycoprotein CD28 Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global T Cell Specific Surface Glycoprotein CD28 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2026) & (K Units) Table 60. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Country (2021-2026) Table 61. Global T Cell Specific Surface Glycoprotein CD28 Sales by Country (2027-2032) & (K Units) Table 62. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Country (2027-2032) Table 63. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Market Share by Country (2021-2026) Table 65. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Market Share by Country (2027-2032) Table 67. Johnson & Johnson Company Information Table 68. Johnson & Johnson Business Overview Table 69. Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 71. Johnson & Johnson Recent Development Table 72. TheraMAB LLC Company Information Table 73. TheraMAB LLC Business Overview Table 74. TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 76. TheraMAB LLC Recent Development Table 77. Five Prime Therapeutics Inc Company Information Table 78. Five Prime Therapeutics Inc Business Overview Table 79. Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 81. Five Prime Therapeutics Inc Recent Development Table 82. Bristol-Myers Squibb Co Company Information Table 83. Bristol-Myers Squibb Co Business Overview Table 84. Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 86. Bristol-Myers Squibb Co Recent Development Table 87. Atox Bio Ltd Company Information Table 88. Atox Bio Ltd Business Overview Table 89. Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Product Portfolio Table 91. Atox Bio Ltd Recent Development Table 92. Key Raw Materials Table 93. Raw Materials Key Suppliers Table 94. T Cell Specific Surface Glycoprotein CD28 Distributors List Table 95. T Cell Specific Surface Glycoprotein CD28 Customers List Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. T Cell Specific Surface Glycoprotein CD28 Product Image Figure 2. Global T Cell Specific Surface Glycoprotein CD28 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032) & (US$ Million) Figure 4. Global T Cell Specific Surface Glycoprotein CD28 Sales (2021-2032) & (K Units) Figure 5. Global T Cell Specific Surface Glycoprotein CD28 Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global T Cell Specific Surface Glycoprotein CD28 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Lulizumab Pegol Image Figure 10. FR-104 Image Figure 11. FPT-155 Image Figure 12. Others Image Figure 13. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share by Type (2021-2032) Figure 16. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type (2021-2032) Figure 19. Plaque Psoriasis Image Figure 20. Acute Renal Failure(ARF) Image Figure 21. Solid Tumor Image Figure 22. Others Image Figure 23. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share by Application (2021-2032) Figure 26. Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application (2021-2032) Figure 29. Global T Cell Specific Surface Glycoprotein CD28 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global T Cell Specific Surface Glycoprotein CD28 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032) & (US$ Million) Figure 34. North America T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032) & (US$ Million) Figure 36. Europe T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032) & (US$ Million) Figure 40. South America T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. T Cell Specific Surface Glycoprotein CD28 Value Chain Figure 128. Manufacturing Cost Structure Figure 129. T Cell Specific Surface Glycoprotein CD28 Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Lulizumab Pegol
  • FR-104
  • FPT-155
  • Others
Applications
  • Plaque Psoriasis
  • Acute Renal Failure(ARF)
  • Solid Tumor
  • Others
Companies covered
  • Johnson & Johnson
  • TheraMAB LLC
  • Five Prime Therapeutics Inc
  • Bristol-Myers Squibb Co
  • Atox Bio Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032)
  4. 1.2.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume (2021-2032)
  5. 1.2.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 T Cell Specific Surface Glycoprotein CD28 Market Dynamics
  1. 2.1 T Cell Specific Surface Glycoprotein CD28 Industry Trends
  2. 2.2 T Cell Specific Surface Glycoprotein CD28 Industry Drivers
  3. 2.3 T Cell Specific Surface Glycoprotein CD28 Industry Opportunities and Challenges
  4. 2.4 T Cell Specific Surface Glycoprotein CD28 Industry Restraints
3 T Cell Specific Surface Glycoprotein CD28 Market by Company
  1. 3.1 Global T Cell Specific Surface Glycoprotein CD28 Company Revenue Ranking in 2025
  2. 3.2 Global T Cell Specific Surface Glycoprotein CD28 Revenue by Company (2021-2026)
  3. 3.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Company (2021-2026)
  4. 3.4 Global T Cell Specific Surface Glycoprotein CD28 Average Price by Company (2021-2026)
  5. 3.5 Global T Cell Specific Surface Glycoprotein CD28 Company Ranking (2024-2026)
  6. 3.6 Global T Cell Specific Surface Glycoprotein CD28 Company Manufacturing Base and Headquarters
  7. 3.7 Global T Cell Specific Surface Glycoprotein CD28 Company Product Type and Application
  8. 3.8 Global T Cell Specific Surface Glycoprotein CD28 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global T Cell Specific Surface Glycoprotein CD28 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 T Cell Specific Surface Glycoprotein CD28 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 T Cell Specific Surface Glycoprotein CD28 Market by Type
  1. 4.1 T Cell Specific Surface Glycoprotein CD28 Type Introduction
  2. 4.1.1 Lulizumab Pegol
  3. 4.1.2 FR-104
  4. 4.1.3 FPT-155
  5. 4.1.4 Others
  6. 4.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Type
  7. 4.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Type (2021-2032)
  9. 4.2.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share by Type (2021-2032)
  10. 4.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Type
  11. 4.3.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Type (2021-2032)
  13. 4.3.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type (2021-2032)
5 T Cell Specific Surface Glycoprotein CD28 Market by Application
  1. 5.1 T Cell Specific Surface Glycoprotein CD28 Application Introduction
  2. 5.1.1 Plaque Psoriasis
  3. 5.1.2 Acute Renal Failure(ARF)
  4. 5.1.3 Solid Tumor
  5. 5.1.4 Others
  6. 5.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Application
  7. 5.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume by Application (2021-2032)
  9. 5.2.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Volume Share by Application (2021-2032)
  10. 5.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Application
  11. 5.3.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Application (2021-2032)
  13. 5.3.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application (2021-2032)
6 T Cell Specific Surface Glycoprotein CD28 Regional Sales and Value Analysis
  1. 6.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Region (2021-2032)
  3. 6.2.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Region: 2021-2026
  4. 6.2.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Region (2027-2032)
  5. 6.3 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Region (2021-2032)
  7. 6.4.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Region: 2021-2026
  8. 6.4.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Region (2027-2032)
  9. 6.5 Global T Cell Specific Surface Glycoprotein CD28 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032)
  12. 6.6.2 North America T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032)
  15. 6.7.2 Europe T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032)
  21. 6.9.2 South America T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa T Cell Specific Surface Glycoprotein CD28 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Country, 2025 VS 2032
7 T Cell Specific Surface Glycoprotein CD28 Country-level Sales and Value Analysis
  1. 7.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2032)
  4. 7.3.1 Global T Cell Specific Surface Glycoprotein CD28 Sales by Country (2021-2026)
  5. 7.3.2 Global T Cell Specific Surface Glycoprotein CD28 Sales by Country (2027-2032)
  6. 7.4 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Country (2021-2032)
  7. 7.4.1 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Country (2021-2026)
  8. 7.4.2 Global T Cell Specific Surface Glycoprotein CD28 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt T Cell Specific Surface Glycoprotein CD28 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt T Cell Specific Surface Glycoprotein CD28 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 TheraMAB LLC
  8. 8.2.1 TheraMAB LLC Company Information
  9. 8.2.2 TheraMAB LLC Business Overview
  10. 8.2.3 TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 TheraMAB LLC T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  12. 8.2.5 TheraMAB LLC Recent Developments
  13. 8.3 Five Prime Therapeutics Inc
  14. 8.3.1 Five Prime Therapeutics Inc Company Information
  15. 8.3.2 Five Prime Therapeutics Inc Business Overview
  16. 8.3.3 Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Five Prime Therapeutics Inc T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  18. 8.3.5 Five Prime Therapeutics Inc Recent Developments
  19. 8.4 Bristol-Myers Squibb Co
  20. 8.4.1 Bristol-Myers Squibb Co Company Information
  21. 8.4.2 Bristol-Myers Squibb Co Business Overview
  22. 8.4.3 Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Co T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Co Recent Developments
  25. 8.5 Atox Bio Ltd
  26. 8.5.1 Atox Bio Ltd Company Information
  27. 8.5.2 Atox Bio Ltd Business Overview
  28. 8.5.3 Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Atox Bio Ltd T Cell Specific Surface Glycoprotein CD28 Product Portfolio
  30. 8.5.5 Atox Bio Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 T Cell Specific Surface Glycoprotein CD28 Value Chain Analysis
  2. 9.1.1 T Cell Specific Surface Glycoprotein CD28 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 T Cell Specific Surface Glycoprotein CD28 Sales Mode & Process
  6. 9.2 T Cell Specific Surface Glycoprotein CD28 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 T Cell Specific Surface Glycoprotein CD28 Distributors
  9. 9.2.3 T Cell Specific Surface Glycoprotein CD28 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst